Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

(2015) Maarten Van Roy et al.   ARTHRITIS RESEARCH & THERAPY

GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety

(2014) R L O’Connor-Semmes et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

(2014) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn)

(2014) Kine Marita Knudsen Sand et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Albumin as a versatile platform for drug half-life extension

(2013) Darrell Sleep et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Binding of transition metal ions to albumin: Sites, affinities and rates

(2013) Wojciech Bal et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

A CHO cell line engineered to express XBP1 and ERO1-Lα has increased levels of transient protein expression

(2013) Katharine Cain et al.   BIOTECHNOLOGY PROGRESS

The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method

(2013) Alison M Clargo et al.   mAbs

Structural and immunologic characterization of bovine, horse, and rabbit serum albumins

(2012) Karolina A. Majorek et al.   MOLECULAR IMMUNOLOGY

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

Impact of albumin on drug delivery — New applications on the horizon

(2011) Bakheet Elsadek et al.   JOURNAL OF CONTROLLED RELEASE

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Allostery in a monomeric protein: The case of human serum albumin

(2010) Paolo Ascenzi et al.   BIOPHYSICAL CHEMISTRY

Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

(2010) A. R. Sørensen et al.   DIABETES OBESITY & METABOLISM

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

(2010) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein

(2010) J. Hopp et al.   PROTEIN ENGINEERING DESIGN & SELECTION

MolProbity: all-atom structure validation for macromolecular crystallography

(2009) Vincent B. Chen et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

New Strategy for the Extension of the Serum Half-Life of Antibody Fragments

(2009) Sabrina Trüssel et al.   BIOCONJUGATE CHEMISTRY

Lessons from the Crystallographic Analysis of Small Molecule Binding to Human Serum Albumin

(2009) Stephen Curry   Drug Metabolism and Pharmacokinetics

High-Throughput Screening for High Affinity Antibodies

(2009) Simon Tickle et al.   Journal of the Association for Laboratory Automation.

Towards Absolute Quantification of Therapeutic Monoclonal Antibody in Serum by LC−MS/MS Using Isotope-Labeled Antibody Standard and Protein Cleavage Isotope Dilution Mass Spectrometry

(2008) Olivier Heudi et al.   ANALYTICAL CHEMISTRY

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

(2008) B. M. Tijink et al.   MOLECULAR CANCER THERAPEUTICS

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

(2008) L. J. Holt et al.   PROTEIN ENGINEERING DESIGN & SELECTION